Toripalimab plus concurrent chemoradiotherapy for recurrent nasopharyngeal carcinoma: A single‐arm, phase 2 clinical trial
Cancer · 2026
DOI: 10.1002/cncr.70257 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2026. Verfasst von Zhehao Xiao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Chemoradiotherapy, Neoplasm Recurrence, Local, Nasopharyngeal Neoplasms. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Shanghai Junshi Biosciences Co., Ltd; Key Research and Development Program Project of Guangxi Zhuang Autonomous Region.
Abstract (Originalsprache)
Background
Improving the efficacy of retreatment for locally recurrent nasopharyngeal carcinoma (rNPC) and extending patient survival are urgently required for the clinical prevention and treatment of NPC. This study explored the efficacy and safety of toripalimab in combination with concurrent chemoradiotherapy (CCRT) for the treatment of rNPC.
Methods
This single‐arm, Phase 2 trial included patients with rNPC who met the inclusion criteria as confirmed by pathology or imaging. The patients received toripalimab combined with CCRT. The primary end point was the objective response rate (ORR) of the patients. Secondary end points included disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), and safety profile.
Results
Between April 2020 and September 2023, 40 patients with rNPC were recruited. The best response of ORR after radiotherapy was 87.5% (95% confidence interval [CI]: 72.0–95.0), with a DCR of 100%. The median PFS for rNPC was 18.1 months (95% CI, 15.2–28.8). The 1‐year, 2‐year, and 3‐year PFS rates were 68.2%, 41.3%, and 15.5%, respectively. The median OS for rNPC was 28.3 months (95% CI, 18.6–Not Available [NA]). The 1‐year, 2‐year, and 3‐year OS rates were 69.7%, 53.9%, 44.8%. The most common acute toxicities were hematological toxicities, including lymphopenia (100%) and anemia (92.5%), whereas the most common late toxicities were dry mouth (60.0%) and nasopharyngeal wall necrosis (40.0%). Fatal epistaxis was the cause of death in 22.5% of patients.
Conclusion
Toripalimab plus CCRT demonstrates antitumor efficacy in rNPC. The observed 22.5% rate of fatal epistaxis indicates that its potential benefits must be carefully weighed against this serious treatment‐related risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
ORCID-Profile: Zhongguo Liang, Ying Guan
Förderung
- Shanghai Junshi Biosciences Co., Ltd; Key Research and Development Program Project of Guangxi Zhuang Autonomous Region
Zitieren
APA
Xiao, Z., Liang, Z., Huang, H., Qin, Y., Huang, S., Wei, J., Guan, Y., Du, Y., Su, F., Li, K., Liu, Y., Wei, J., Zeng, F., Li, Y., Wei, C., Mo, Y., Yu, B., & Qu, S. (2026). Toripalimab plus concurrent chemoradiotherapy for recurrent nasopharyngeal carcinoma: A single‐arm, phase 2 clinical trial. Cancer. https://doi.org/10.1002/cncr.70257
Vancouver
Xiao Z, Liang Z, Huang H, Qin Y, Huang S, Wei J, et al. Toripalimab plus concurrent chemoradiotherapy for recurrent nasopharyngeal carcinoma: A single‐arm, phase 2 clinical trial. Cancer. 2026. doi:10.1002/cncr.70257
BibTeX
@article{Xiao2026,
author = {Xiao, Zhehao and Liang, Zhongguo and Huang, Hejing and Qin, Yumei and Huang, Shiting and Wei, Jingni and Guan, Ying and Du, Youqin and Su, Fang and Li, Kaiguo and Liu, Yang and Wei, Junbao and Zeng, Fanyan and Li, Ye and Wei, Chunmi and Mo, Yanlin and Yu, Binbin and Qu, Song},
title = {Toripalimab plus concurrent chemoradiotherapy for recurrent nasopharyngeal carcinoma: A single‐arm, phase 2 clinical trial},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70257}
}
EUVIMED